Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -11.52 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | 1862.97 | — |
| — | — | — | — | — | — | — | — | — | — | — | +1657.3% | — | |
| P/B Ratio | 18.83 | 19.85 | 79.89 | 60.91 | 41.35 | 33.86 | 36.34 | 28.31 | 65.72 | 23.57 | 13.13 | 14.64 | 4.96 |
| — | -41.4% | +119.8% | +115.2% | -37.1% | +43.7% | +176.8% | +93.3% | +1225.5% | +232.8% | +889.4% | +654.0% | +32.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 56.30 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 54.37 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | -100.4% | — |
| — | — | — | — | — | — | — | — | — | — | — | -222.2% | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | -6720.9% | — |
| — | — | — | — | — | — | — | — | — | — | — | -24.4% | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | -6262.6% | — |
| — | — | — | — | — | — | — | — | — | — | — | +12.2% | — |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -206.1% | -51.5% | -102.6% | -187.4% | -17.2% | -14.8% | -17.8% | -50.5% | -71.3% | -32.4% | -19.4% | -11.6% | -417.0% |
| — | -247.8% | -477.4% | -271.3% | +75.9% | +54.3% | +8.5% | -334.0% | +82.9% | -119.0% | +16.2% | +59.9% | -1339.1% | |
| ROA | -181.9% | -43.3% | -79.1% | -159.8% | -15.4% | -13.0% | -13.3% | -23.3% | -22.9% | -13.6% | -9.3% | -6.0% | -118.0% |
| — | -231.8% | -494.2% | -586.4% | +32.9% | +4.2% | -42.7% | -289.4% | +80.6% | -190.1% | +45.2% | +62.2% | -533.9% | |
| ROIC | -163.4% | 20.8% | — | -801.6% | -23.3% | -14.7% | -13.4% | -24.3% | -31.0% | -14.5% | -8.4% | -6.7% | -173.8% |
| — | +241.0% | — | -3193.8% | +24.9% | -1.9% | -59.7% | -261.0% | +82.1% | -48.4% | +87.8% | +87.3% | -50.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Summit Therapeutics Inc.'s Debt/EBITDA ratio is 0.4x — comfortably within a safe range. Debt/Equity has risen for 4 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.07 | 0.56 | 2.48 | 1.37 | 1.07 | 0.90 | 0.78 |
| — | +70.8% | -62.0% | -96.2% | -99.2% | -98.6% | -93.1% | -37.9% | +217.4% | -66.7% | +3176.3% | +68.5% | +82.8% | |
| Debt / EBITDA | — | 0.37 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.87 | 9.87 | 3.80 | 5.13 | 10.63 | 10.15 | 8.31 | 2.35 | 6.97 | 9.30 | 1.80 | 19.07 | 14.22 |
| — | -2.8% | -54.3% | +118.5% | +52.6% | +9.2% | +361.1% | -87.7% | -51.0% | -45.1% | -78.1% | +264.4% | +225.0% | |
| Quick Ratio | 9.87 | 9.87 | 3.80 | 5.13 | 10.63 | 10.15 | 8.31 | 2.35 | 6.95 | 9.30 | 1.76 | 18.56 | 14.22 |
| — | -2.8% | -54.3% | +118.5% | +52.9% | +9.2% | +372.8% | -87.4% | -51.1% | -45.1% | -78.4% | +254.6% | +239.8% | |
| Interest Coverage | — | — | — | — | — | -7290.44 | -23.67 | -19.22 | -13.58 | -9.80 | -7.53 | -6.28 | -64.51 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonSummit Therapeutics Inc.'s current P/E is -11.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Summit Therapeutics Inc.'s business trajectory between earnings reports.